期刊文献+

大剂量米非司酮对绝经后子宫内膜息肉的雌、孕激素受体及Ki-67、Bcl-2的影响 被引量:7

Effect of large dose mifepristone on the expression of estrogen receptors,progesterone receptors,Bcl-2 and Ki-67 in postmenopausal endometrial polyps
下载PDF
导出
摘要 目的:通过检测米非司酮(RU486)治疗绝经后子宫内膜息肉(EP)前后的雌、孕激素受体(ER、PR)及Ki-67、Bcl-2水平变化,探讨子宫内膜息肉的药物治疗方法。方法:绝经后子宫内膜息肉患者458例,均接受宫腔镜下子宫内膜息肉切除术(TCRP),术后病理诊断均为子宫内膜息肉,并采用免疫组化法检测子宫内膜息肉中雌、孕激素受体及Ki-67、Bcl-2的表达;随访以上患者,术后3个月~3年复发160例(经宫腔镜检查),均予大剂量米非司酮口服治疗,3个月后行宫腔镜检查,有残余息肉者55例,再行TCRP,并采用免疫组化法检测子宫内膜息肉中雌、孕激素受体及Ki-67、Bcl-2的表达。结果:米非司酮治疗复发子宫内膜息肉160例,105例EP消失,55例EP缩小,子宫内膜息肉中雌、孕激素受体及Ki-67的表达均较服药前明显降低,而Bcl-2变化不大。结论:大剂量米非司酮通过降调子宫内膜息肉中雌、孕激素受体及Ki-67的表达而有效治疗子宫内膜息肉。 Objective:To explore the expression of estrogen receptors(ER),progesterone receptors(PR),Bel-2 and Ki-67 in postmenopausal endometrial polyps before and after the treatment by large dose mifepristone (RU486).Methods: 458 post-menopausal endometrial polyps were all treated by transcervical recection of polyp(TCRP),and diagnosed by pathology.The presence of ER,PR, Bel-2 and Ki-67 were detected by immunohistochemical staining.Following up these cases, 160 cases reeured in three months to three years after treatment.These recurrence were treated by large dose mifepristone .After three months, 55 cases remainder EP were detected by hysteroseopy and treated by TCRP, then detected the presence of above receptors in the same way.Results: Among the 160 recurrence EP treated by RU486,105 cases were disappeared and 55 cases contracted.The presence of ER,PR and Ki-67 were obviously depressed,and Bel-2 had no significantly change. Conclusion: Large dose mifepristone can treat the utily EP by lowering the presence of ER,PR and Ki-67.
作者 吴小容
出处 《中国医药导报》 CAS 2008年第17期40-41,共2页 China Medical Herald
关键词 米非司酮 绝经后子宫内膜息肉 雌激素受体 孕激素受体 Mifepristone Postmenopausal endometrial polyp Estrogen receptor Progesterone receptor
  • 相关文献

参考文献4

二级参考文献43

  • 1张晓红,胡梅林,崔恒,魏丽惠.子宫内膜息肉213例分析[J].中国妇产科临床杂志,2003,4(6):413-415. 被引量:3
  • 2[1]Kommoss F, Karck U, Prmpeler H, et al. Steroid receptor expression in endometria from women treated with tamoxifen[J]. Gynecologic oncology, 1998,70(2):188-191.
  • 3[2]Kim MR, Kim YA, Jo MY, et al. High frequency of endometrial polyps in endometriosis[J]. J Am Assoc Gynecol Laparosc, 2003,10(1):46-48.
  • 4[3]Savelli L, De Iaco P, Santini D, et al. Hystopathologic features and risk factors for benignity, hyperplasia, and cancer in endometrial polyps[J]. J Am Assoc Gynecol Laparosc,2003,188(4):927-931.
  • 5[4]Bouda J Jr, Hradecky L, Rokyta Z. Hysteroscopic polypectomy versus fractionated curettage in the treatment of corporal polyps-recurrence of corporal polyps[J]. Ceska Gynekol,2000,65(3):147-151.
  • 6[5]Mittal K, Schwartz L, Goswami S, et al. Estrogen and progesterone receptor expression in endometrial polyps[J]. Int J Gynecol Pathol,1996,15(4):345-348.
  • 7[6]Maia H, Maltez A, Athayde C, et al. Proliferation profile of endometrial polyps in post-menopausal women[J]. Maturitas,2001,40(3):273-281.
  • 8[7]Tallini G , Vanni R, Ianfioletti G, et al. HMGI-C and HMGI(Y) immunoreactivity correlates with cytogenetic abnormalities in lipomas,pulmonary chondroid hamartomas,endometrial polyps,and uterine leiomyomas and is compatible with rearrangement of the HMGI-C and HMGI(Y) genes[J]. Lab Invest,2000,80(1):359-369.
  • 9[8]Goldenberg M, Nezhat C, Seidman DS. A randomized prospective study of the use of endometrial ablation for prevention of recurrent endometrial polyps in breast cancer patients receiving tamoxifen[J]. Prim Care Update Ob Gyns,1998,5(4):160.
  • 10[9]DeWaay DJ, Syrop CH,Nygaard IE,et al. Natural history of uterine polyps and leiomyomata[J]. Obstet Gynecol,2002,100(1):3-7.

共引文献48

同被引文献74

引证文献7

二级引证文献75

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部